The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation trial of SRS boost treatment of human papilloma virus (HPV)-unassociated oropharyngeal squamous cell carcinoma (OPSCC).
David L. Schwartz
Research Funding - Resonant Medical; SciClone
Sara Parise
No relevant relationships to disclose
Jordan Denitz
No relevant relationships to disclose
Vinh Nguyen
No relevant relationships to disclose
John Fantasia
No relevant relationships to disclose
Bhoomi Mehrotra
No relevant relationships to disclose
Benjamin Saltman
No relevant relationships to disclose
Douglas Frank
No relevant relationships to disclose